Can a new daily pill lift the fog of depression?

NCT ID NCT07741240

Not yet recruiting Disease control Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This clinical trial is testing an experimental oral medication called KH607 in adults with major depressive disorder. Participants will receive either KH607 or a placebo once daily for several weeks, and researchers will measure changes in depression severity using a standard rating scale. The study aims to see if KH607 is safe and effective in reducing depressive symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KH607 tablets (an experimental oral drug taken once daily)
What this could lead to: If successful, KH607 could offer a new oral treatment option for major depressive disorder, potentially helping people who don't respond to existing antidepressants.
What could go wrong: This is a phase 3 trial, but success is not guaranteed. The drug may not prove more effective than placebo, and side effects are possible. Results from this trial will need confirmation before any approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

More trials for these conditions

Other studies related to the condition(s) this trial covers.